Reveal the unexplored regulators of anticancer immunity
OREGA Biotech translates cancer science into first-in-class monoclonal antibodies that restore the immune system's ability to recognise and destroy tumours.
Transforming cancer science into novel immunotherapies.
OREGA Biotech specialises in the discovery and development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform discovers and validates novel immune checkpoint inhibitors and regulators of anti-PD-1 response.
Founded in 2010 on the research of our academic co-founders, we establish preclinical proof of concept on new targets, then partner early with larger biotech and pharmaceutical companies.
Our anti-CD39 program has been licensed to Innate Pharma, then partnered with AstraZeneca.
Science & innovation
for the benefit
of patients
From target discovery to patients
We are developing two first-in-class programs that target the immunosuppressive tumour microenvironment and resistance to anti-PD-1 therapy.
Anti-CD39 mAb
IPH5201 · adenosine pathwayNovel target
Inducing TLS & immunityAnti-CD39 mAb
Phase 2Novel target
PreclinicalBlocking the adenosine switch
Dying tumour cells release ATP, a danger signal that calls the immune system into action. CD39, expressed on regulatory T cells and tumour cells, degrades that ATP into immunosuppressive adenosine — letting the tumour escape.
Our humanised blocking antibody inhibits both membrane-bound and soluble CD39: adenosine production falls, ATP accumulates, and immune-mediated killing of cancer cells is restored.
Building immune hubs inside refractory tumours
Our second program targets an undisclosed regulator of B-cell responses. Releasing this brake promotes germinal centre formation and the development of tertiary lymphoid structures (TLS) — organised immune hubs within tumours that are strongly associated with response to immune checkpoint blockade.
The underlying biology is well established, and our lead candidate is a humanised, first-in-class monoclonal antibody.
A science-to-deal track record
OREGA Biotech founded; CD39 program initiated.
CD39 program licensed to Innate Pharma.
Partnered with AstraZeneca.
IPH5201 enters Phase 1.
First patient dosed in Phase 2 MATISSE.
Interim Phase 2 results in plenary at AACR.
Exclusive worldwide licence · 2016
Co-development partner · 2018Builders and scientists
A team combining drug development, company building and decades of INSERM research in tumour immunology.
Jeremy Bastid
PharmD, PhD in Oncology, specialised in immuno-oncology; research at INSERM U590, Lyon.
Gilles Alberici
PharmD, PhD in Immunology; serial founder of biopharma companies; manages OCTALFA since 2006.
Nathalie Bonnefoy
PhD, INSERM Research Director; leads the Immunity & Cancer team at IRCM Montpellier; 80+ publications.
Armand Bensussan
PhD; directs the Skin Research Center and INSERM U976 at Hôpital Saint-Louis, Paris; 340 publications.
